{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:13:39Z","timestamp":1771060419084,"version":"3.50.1"},"reference-count":57,"publisher":"Georg Thieme Verlag KG","issue":"07\/08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>In den letzten Jahren erlebte die klinische Forschung zur therapeutischen\n                    Wirksamkeit von Psychedelika eine Art Renaissance. Der aktuelle Stand\n                    wissenschaftlicher Erkenntnisse zur Wirksamkeit bei verschiedenen\n                    psychiatrischen Indikationen, wie auch die bereits unter bestimmten\n                    Voraussetzungen genehmigungsf\u00e4hige Anwendung einiger psychedelischer\n                    Substanzen in der klinischen Praxis in manchen L\u00e4ndern der Welt, legen\n                    die M\u00f6glichkeit einer zuk\u00fcnftigen Anwendung im klinischen\n                    Setting auch in Deutschland nahe. Dabei steht das Feld noch vor gro\u00dfen\n                    Herausforderungen inklusive der Notwendigkeit einer kritischen Gestaltung der\n                    Rahmenbedingungen f\u00fcr einen m\u00f6glichen klinischen Einsatz. In\n                    diesem Artikel wird auf die historischen Hintergr\u00fcnde der klinischen\n                    Anwendung von Psychedelika eingegangen, um dann Aspekte wie\n                    Psychoph\u00e4nomenologie, Wirkmodelle, m\u00f6gliche Indikationen und\n                    Pharmakosicherheit zu beleuchten. Anschlie\u00dfend wird der aktuelle Stand\n                    der Forschung und auch der Organisation von Fachgesellschaften in Deutschland im\n                    historischen und internationalen Kontext betrachtet, wie auch kritische Aspekte\n                    und noch zu kl\u00e4rende Fragen in dem Themenfeld.<\/jats:p>","DOI":"10.1055\/a-1981-3152","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T01:20:13Z","timestamp":1672881613000},"page":"311-318","source":"Crossref","is-referenced-by-count":6,"title":["Psychedelika in der Psychiatrie \u2013 Entwicklungen und die\n                    Stellung in Deutschland"],"prefix":"10.1055","volume":"91","author":[{"given":"Uwe","family":"Herwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Mertens","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Molekulares Neuroimaging, Zentralinstitut\n                    f\u00fcr Seelische Gesundheit, Medizinische Fakult\u00e4t Mannheim,\n                    Universit\u00e4t Heidelberg, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio P\u00e9rez","family":"Rosal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Koller","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie,\n                    Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Jungaberle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Borgwardt","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie,\n                    Universit\u00e4tsklinikum Schleswig Holstein, Universit\u00e4t zu\n                    L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a\n                    randomized clinical trial","volume":"78","author":"A K Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamapsychiatry.2021.0500","article-title":"How COVID-19 Affects the Brain","volume":"78","author":"M Boldrini","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref4","first-page":"411","article-title":"\u00dcber Anhalonium Lewinii","volume":"24","author":"Louis Lewin","year":"1887","journal-title":"Archiv f\u00fcr experimentelle Pathologie und\n                    Pharmakologie"},{"key":"ref5","first-page":"327","article-title":"Ueber Pellotin","volume":"10","author":"A Heffter","year":"1896","journal-title":"Therapeutische Monatshefte"},{"key":"ref8","volume-title":"LSD \u2013 mein Sorgenkind","author":"A Hofmann","year":"1979"},{"key":"ref9","first-page":"279","article-title":"Lysergs\u00e4ure-Di\u00e4thylamid, ein Phantasticum aus der\n                    Mutterkorngruppe","volume":"60","author":"W A Stoll","year":"1947","journal-title":"Archiv f\u00fcr Neurologie und Psychiatrie"},{"key":"ref10","volume-title":"Halluzinogene. Psychische Grenzzust\u00e4nde in Therapie und Forschung","author":"H Leuner","year":"1981"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"JJ H Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref12","first-page":"1","article-title":"The early use of MDMA (\u201aEcstasy\u2019) in psychotherapy\n                    (1977\u20131985)","volume":"4","author":"T Passie","year":"2018","journal-title":"Drug, Science and Law"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","article-title":"Differences between the Mechanism of Action of MDMA, MDBD and the Classic\n                    Hallucinogens","volume":"18","author":"D E Nichols","year":"1986","journal-title":"Journal of Psychoactive Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/dta.2292","article-title":"MDA, MDMA, and other \"mescaline-like\" substances in the US\n                    military\u2019s search for a truth drug (1940s to 1960s)","author":"T Passie","year":"2018","journal-title":"Drug Test Anal"},{"key":"ref15","first-page":"59","article-title":"Die psycholytische Psychotherapie in der Schweiz von 1988-1993. Eine\n                    katamnestische Erhebung","volume":"147","author":"P Gasser","year":"1996","journal-title":"Schweizer Archiv f\u00fcr Neurologie und\n                    Psychiatrie"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood\n                    disorders","volume":"11","author":"F X Vollenweider","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00115-021-01255-1","article-title":"Sind Psychedelika schnell wirksame Antidepressiva? [Are psychedelics fast acting\n                    antidepressant agents?]","volume":"93","author":"G Gr\u00fcnder","year":"2022","journal-title":"Nervenarzt"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.nsa.2022.100104","article-title":"Methodological Challenges in Psychedelic Drug Trials: Efficacy and Safety of\n                    Psilocybin in Treatment-Resistant Major Depression (EPIsoDE) \u2013 Rationale\n                    and Study Design","volume":"1","author":"L J Mertens","year":"2022","journal-title":"Neurosci Applied"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind,\n                    placebo-controlled phase 3 study","volume":"27","author":"J M Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1055\/s-0043-103085","article-title":"Psychotherapie mit adjuvanter Gabe von serotonergen psychoaktiven Substanzen\n                    \u2013 M\u00f6glichkeiten und Hindernisse [Psychotherapy with Adjuvant use\n                    of Serotonergic Psychoactive Substances: Possibilities and Challenges]","volume":"85","author":"T Maji\u0107","year":"2017","journal-title":"Fortschr Neurol Psychiatr"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"American Psychiatric Association (APA) Council of Research Task Force on Novel\n                    Biomarkers and Treatments. A Consensus Statement on the Use of Ketamine in the\n                    Treatment of Mood Disorders","volume":"74","author":"G Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and\n                    Outcomes in Three Large Practices Administering Ketamine with Psychotherapy","volume":"51","author":"J Dore","year":"2019","journal-title":"J Psychoactive Drugs"},{"key":"ref24","first-page":"391","article-title":"the Work Group on Biomarkers and Novel Treatments, a Division of the American\n                    Psychiatric Association Council of Research. Psychedelics and\n                    Psychedelic-Assisted Psychotherapy","volume":"177","author":"C M Reiff","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness\n                    (ASCs) in humans","volume":"31","author":"A Dittrich","year":"1998","journal-title":"Pharmacopsychiatry."},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fpsyg.2018.01028","article-title":"The Altered States Database: Psychometric Data of Altered States of\n                    Consciousness","volume":"9","author":"T T Schmidt","year":"2018","journal-title":"Front Psychol"},{"key":"ref27","first-page":"155","article-title":"A taxonomy of ecstatic states in the context of psychotherapy with psychedelic\n                    substances","volume":"256","author":"T Passie","year":"2019","journal-title":"Journal of Consciousness Studies"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind\n                    placebo-controlled study in healthy subjects","volume":"46","author":"F Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and\n                    psilocybin in a double-blind placebo-controlled study in healthy subjects","author":"F Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/1570159X16666180125095902","article-title":"Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential\n                    Uses in Addiction and Mental Illness","volume":"17","author":"J Hamill","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","article-title":"Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced\n                    Positive Mood in Healthy Volunteers","volume":"78","author":"R Kraehenmann","year":"2015","journal-title":"Biol Psychiatry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e1084","DOI":"10.1038\/tp.2017.54","article-title":"Acute effects of LSD on amygdala activity during processing of fearful stimuli\n                    in healthy subjects","volume":"7","author":"F M\u00fcller","year":"2017","journal-title":"Transl Psychiatry"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0269881119895520","article-title":"Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal\n                    functional connectivity during emotional processing after psilocybin for\n                    treatment-resistant depression","volume":"34","author":"L J Mertens","year":"2020","journal-title":"J Psychopharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/acps.12818","article-title":"Increased thalamic resting-state connectivity as a core driver of LSD-induced\n                    hallucinations","volume":"136","author":"F M\u00fcller","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.nicl.2018.03.005","article-title":"Altered network hub connectivity after acute LSD administration","volume":"18","author":"F M\u00fcller","year":"2018","journal-title":"Neuroimage Clin"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: neurobiology and potential for treatment of psychiatric\n                    disorders","volume":"21","author":"F X Vollenweider","year":"2020","journal-title":"Nat Rev Neurosci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with\n                    psilocybin","volume":"109","author":"R L Carhart-Harris","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","article-title":"Neural correlates of the LSD experience revealed by multimodal neuroimaging","volume":"113","author":"R L Carhart-Harris","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e0118143","DOI":"10.1371\/journal.pone.0118143","article-title":"The psychedelic state induced by ayahuasca modulates the activity and\n                    connectivity of the default mode network","volume":"10","author":"F Palhano-Fontes","year":"2015","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1038\/s41598-019-50612-3","article-title":"Characterization and prediction of acute and sustained response to psychedelic\n                    psilocybin in a mindfulness group retreat","volume":"9","author":"L Smigielski","year":"2019","journal-title":"Sci Rep"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/YCO.0000000000000467","article-title":"How do psychedelics work?","volume":"32","author":"R L Carhart-Harris","year":"2019","journal-title":"Curr Opin Psychiatry"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fpsyt.2020.00005","article-title":"Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy\n                    Promotes Acceptance","volume":"11","author":"M Wolff","year":"2020","journal-title":"Front Psychiatry"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neuropharm.2018.06.034","article-title":"Positive psychology in the investigation of psychedelics and entactogens: A\n                    critical review","volume":"142","author":"H Jungaberle","year":"2018","journal-title":"Neuropharmacology."},{"key":"ref44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","article-title":"Psychological flexibility mediates the relations between acute psychedelic\n                    effects and subjective decreases in depression and anxiety","volume":"15","author":"A K Davis","year":"2020","journal-title":"J Contextual Behav Sci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.31234\/osf.io\/u6v9y","article-title":"Yale Manual for Psilocybin-assisted Therapy of Depression","author":"J Guss","year":"2020"},{"key":"ref46","first-page":"241","article-title":"L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug","volume":"11","author":"A K Busch","year":"1950","journal-title":"Dis Nerv Syst"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1176\/ajp.108.12.896","article-title":"Lysergic acid diethylamide; a clinical-psychological study","volume":"108","author":"C Savage","year":"1952","journal-title":"Am J Psychiatry"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1192\/bjp.103.431.332","article-title":"Further studies in the therapeutic value of lysergic acid diethylamide in mental\n                    illness","volume":"103","author":"R A Sandison","year":"1957","journal-title":"J Ment Sci"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"406","DOI":"10.15288\/qjsa.1958.19.406","article-title":"A new adjunct to the treatment of alcoholism: the hallucinogenic drugs","volume":"19","author":"C M Smith","year":"1958","journal-title":"Q J Stud Alcohol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881112456611","article-title":"Durability of improvement in post-traumatic stress disorder symptoms and absence\n                    of harmful effects or drug dependency after\n                    3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective\n                    long-term follow-up study","volume":"27","author":"M C Mithoefer","year":"2013","journal-title":"J Psychopharmacol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3390\/ijms17111953","article-title":"d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action\n                    and Pharmacology","volume":"17","author":"D De Gregorio","year":"2016","journal-title":"Int J Mol Sci"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an\n                    open-label feasibility study","volume":"3","author":"R L Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"R Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept\n                    study","volume":"29","author":"M P Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","article-title":"Reviewing the Potential of Psychedelics for the Treatment of PTSD","volume":"23","author":"E Krediet","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09540261.2021.1919062","article-title":"Psilocybin and MDMA for the treatment of trauma-related psychopathology","volume":"33","author":"CI V Bird","year":"2021","journal-title":"Int Rev Psychiatry"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose\n                    Deaths Among US Adults","volume":"78","author":"B Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the\n                    management of mood, anxiety, and substance-use disorders: a systematic review of\n                    systematic reviews","volume":"11","author":"R G Dos Santos","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","article-title":"Psychedelic medicine: safety and ethical concerns","volume":"10","author":"B T Anderson","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/a-1486-7386","article-title":"The Potential Role of Psychedelic Drugs in Mental Health Care of the Future","volume":"54","author":"G Gr\u00fcnder","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"586682","DOI":"10.3389\/fpsyt.2021.586682","article-title":"Development and Evaluation of a Therapist Training Program for Psilocybin\n                    Therapy for Treatment-Resistant Depression in Clinical Research","volume":"12","author":"S J Tai","year":"2021","journal-title":"Front Psychiatry"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1981-3152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T21:07:23Z","timestamp":1719522443000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1981-3152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":57,"journal-issue":{"issue":"07\/08","published-online":{"date-parts":[[2023,7,18]]},"published-print":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1981-3152","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]}}}